Synthaverse S.A. (FRA:6NQ)

Market Cap	65.64M -8.3%
Revenue (ttm)	16.77M +22.4%
Net Income	1.76M +58.7%
EPS	n/a
Shares Out	n/a
PE Ratio	37.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.9270
Previous Close	0.9370
Day's Range	0.9240 - 0.9370
52-Week Range	0.7090 - 1.3780
Beta	n/a
RSI	51.16
Earnings Date	Apr 30, 2026

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1944
• Employees: 239
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6NQ

Financial Performance

In 2024, Synthaverse's revenue was 71.76 million, an increase of 22.44% compared to the previous year's 58.61 million. Earnings were 7.55 million, an increase of 58.68%.

Financial numbers in PLN